2014 PBAC submissions and outcomes – winners and losers
Michael Wonder - January 2015
www.maestrodatabase.com
Submissions
The PBAC considered 170 submissions in 2014 of which 168 were prepared
and lodged by the pharmaceutical industry (sponsors of medicines and medicinal
preparations).
88 (52%) of the 133 submissions were major submissions and 82 (48%) were
minor submissions.
Outcomes
The 170 submissions yielded 244
outcomes. The number of PBAC outcomes
from a given PBAC meeting or analysis period may be greater than the number of
submissions for the same meeting or analysis period as some submissions may
have contained multiple requests and/or multiple patient populations.
Of the 244 outcomes, 157 (64%) were
recommendations, 57 (23%) were rejections and 30 (12%) were deferrals.
Winners and
losers
The
winners for 2014 were MSD (20 recommendations from 6 submissions), Novartis (12
recommendations from 10 submissions), Roche (11 recommendations from 10 submissions)
and GSK (8 recommendations from 12 submissions).
The losers
for 2014 were Gilead (13 rejections from 1 submission), Sanofi (4 rejections
from 3 submissions) and Bayer (4 rejections from 9 submissions).
©
Wonder Drug Consulting Pty Ltd, 2015.
